These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35074332)

  • 21. Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics.
    Jacob JJ; John Fletcher G; Monisha Priya T; Veeraraghavan B; Mutreja A
    Indian J Med Microbiol; 2021; 39(4):417-422. PubMed ID: 34454775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design.
    Groves DC; Rowland-Jones SL; Angyal A
    Biochem Biophys Res Commun; 2021 Jan; 538():104-107. PubMed ID: 33199022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel SARS-CoV-2 variants: the pandemics within the pandemic.
    Boehm E; Kronig I; Neher RA; Eckerle I; Vetter P; Kaiser L;
    Clin Microbiol Infect; 2021 Aug; 27(8):1109-1117. PubMed ID: 34015535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omicron: a drug developer's perspective.
    Fang FF; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):208-211. PubMed ID: 34951568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Covid-19, an unfinished story.
    Buisson Y
    Presse Med; 2022 Sep; 51(3):104131. PubMed ID: 35667598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
    Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
    Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 variants - Evolution, spike protein, and vaccines.
    Chen KK; Tsung-Ning Huang D; Huang LM
    Biomed J; 2022 Aug; 45(4):573-579. PubMed ID: 35526825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?
    Duong BV; Larpruenrudee P; Fang T; Hossain SI; Saha SC; Gu Y; Islam MS
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19.
    Kumar A; Parashar R; Kumar S; Faiq MA; Kumari C; Kulandhasamy M; Narayan RK; Jha RK; Singh HN; Prasoon P; Pandey SN; Kant K
    J Med Virol; 2022 Apr; 94(4):1300-1314. PubMed ID: 34811761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model.
    Pulit-Penaloza JA; Belser JA; Sun X; Pappas C; Brock N; Kieran TJ; Ritter JM; Seixas JN; Jones J; Basu Thakur P; Pusch E; Wang L; Tumpey TM; Wentworth DE; Zhou B; Maines TR
    mBio; 2022 Oct; 13(5):e0242122. PubMed ID: 36135377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants.
    Satta S; Shahabipour F; Gao W; Lentz SR; Perlman S; Ashammakhi N; Hsiai T
    Theranostics; 2022; 12(10):4779-4790. PubMed ID: 35832078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?
    Abas AH; Marfuah S; Idroes R; Kusumawaty D; Fatimawali ; Park MN; Siyadatpanah A; Alhumaydhi FA; Mahmud S; Tallei TE; Emran TB; Kim B
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.